Albumin Patents (Class 530/362)
  • Patent number: 10286039
    Abstract: The invention relates methods of using a retinoid agonist and a G-CSF or an analog thereof to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of a condition in a subject. The retinoid agonist and the G-CSF or the analog thereof may be provided in a single composition or in separate compositions. A therapeutically effective amount of the retinoid agonist and the G-CSF or the analog thereof may be administered to the subject concurrently or sequentially. Conditions treatable with the methods and compositions include but are not limited to various forms of neutropenia and microbial infections. The invention also relates to methods for determining the efficacy of the treatments described herein.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: May 14, 2019
    Assignee: Children's Hospital Los Angeles
    Inventor: Lingtao Wu
  • Patent number: 9937152
    Abstract: The present invention provides a group of novel SMA derivatives and a covalent conjugate of the derivatives and an active substance. More specifically, the present invention provides: an SMA derivative which contains (i) a styrene-maleic acid copolymer (SMA) and (ii) a side chain (b) that contains a functional group (a) selected from among —NH2, —SH, —OH, —COOH, —NH—(C?NH)—NH2 and —C(CH2—OH)3 and introduced into a carboxyl group of a maleic acid residue of the SMA via an amide bond or an ester bond, and wherein when a plurality of side chain (b) is introduced into the SMA, the side chains (b) may be identical or different from each other; and a conjugate of this SMA derivative and an active substance.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: April 10, 2018
    Inventor: Hiroshi Maeda
  • Patent number: 9504714
    Abstract: The present invention relates to a method for treating blood plasma including the steps of ethanol precipitation of the plasma or a fraction of plasma, recovering the precipitate, washing said precipitate, recovering a washed plasma paste, and making said washed plasma paste soluble.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: November 29, 2016
    Assignee: LFB Biomedicaments
    Inventor: Thierry Trusgnich
  • Patent number: 9364443
    Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises an opsonin, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: June 14, 2016
    Assignees: BAXTER INTERNATIONAL, INC., BAXTER HEALTHCARE SA, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Arnaud Beduneau, Howard Gendelman, Barrett Rabinow, Jane Werling
  • Publication number: 20150125859
    Abstract: Provided is a nucleic acid chromatography method ensuring a stable detection state, and a composition and kit for use in nucleic acid chromatography. For this purpose, the nucleic acid chromatography method is provided with a step of performing chromatography by supplying a chromatography liquid containing a target nucleic acid to a solid-phase carrier on which is fixed a detection probe capable of capturing the nucleic acid, wherein the chromatography liquid contains one or two or more kinds of water-soluble polymers.
    Type: Application
    Filed: December 31, 2014
    Publication date: May 7, 2015
    Applicant: NGK INSULATORS, LTD.
    Inventors: Akinobu Oribe, Kousuke Niwa, Toshikazu Hirota
  • Patent number: 9023990
    Abstract: A method for separating and purifying recombinant human serum albumin (rHSA) from transgenic rice grain, sequentially comprising the steps of: 1) subjecting crude extract of rHSA to cation exchange chromatography to obtain primary product I; 2) subjecting the primary product I to anion exchange chromatography to obtain secondary product II; 3) subjecting the secondary product II to hydrophobic chromatography to obtain purified rHSA. The method may further comprise a step of ceramic hydroxyapatite chromatography prior to the hydrophobic chromatography. The method has the advantages of low cost and easy operation. The resultant rHSA has a purity of about 99% by HPLC.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: May 5, 2015
    Assignee: Healthgen Biotechnology Co., Ltd.
    Inventors: Daichang Yang, Yang He, Guangfei Li, Jingru Liu
  • Patent number: 9023991
    Abstract: The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: May 5, 2015
    Assignee: Araclon Biotech B.L.
    Inventor: J. Manuel Sarasa Barrio
  • Patent number: 9012518
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Patent number: 9012519
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Patent number: 8980826
    Abstract: The present invention relates to a method of promoting bronchodilation by administration of streptolysin O to a subject in need thereof.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: March 17, 2015
    Assignee: Beech Tree Labs, Inc.
    Inventor: John McMichael
  • Publication number: 20150023960
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 22, 2015
    Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
  • Publication number: 20150017699
    Abstract: The present invention is generally directed to internally functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention is a graphene substrate. The substrate comprises edge and non-edge regions. Organic or inorganic molecules are bound to the non-edge regions of the substrate, and the organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm2.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 15, 2015
    Applicant: NANOTECH BIOMACHINES, INC.
    Inventors: Jeffrey Alan McKinney, William Emerson Martinez
  • Publication number: 20150010494
    Abstract: A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Gord Adamson, David Bell, Steven Brookes
  • Patent number: 8901017
    Abstract: Binder compositions are described, where the compositions include a protein, a first crosslinking compound that includes a carbohydrate, and a second crosslinking compound that includes two or more primary amine groups. The first and second crosslinking compounds may be individually crosslinkable with each other and with the protein. Also described are fiber products that may include inorganic or organic fibers and a cured thermoset binder prepared from a protein and at least two crosslinking compounds. Additionally, methods of making fiber products are described that include providing inorganic or organic fibers, and applying a liquid binder composition to the fibers to form a fiber-binder amalgam. The liquid binder composition may include a protein and at least two crosslinking compounds that include a carbohydrate and an organic amine with two or more primary amines. The amalgam may be heated to a curing temperature to form the fiber product.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: December 2, 2014
    Assignee: Johns Manville
    Inventors: Mingfu Zhang, Jawed Asrar, Uranchimeg Lester
  • Publication number: 20140343253
    Abstract: There is a recognized need for novel, more simplified, approaches to isolation of plasma from whole blood, as well as a need to isolate cell-free plasma fractions containing different plasma proteins. Methods are divulged for use of aqueous phase systems, formed in blood or blood containing solutions via addition of a single polymer at relatively low concentration, to effect isolation (clarification) of plasma proteins from blood cells. Methods are also divulged to replace widely used Cohn-type plasma protein fractionation which is based on sequential addition of up to 40% (v/v) ethanol and other precipitants, with simple sequential addition of a polyacid. The latter results in isolation of plasma protein fractions (i.e. fibrinogen, immunoglobulin, albumin) in sequence similar to that obtained with Cohn Fractionation and therefore may be suitable for use to reduce solvent use and solvent-related process complications in existing plasma protein purification processes.
    Type: Application
    Filed: September 14, 2012
    Publication date: November 20, 2014
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: James Van Alstine, Mikael Berg, Johanna Kjorning, JAMIL Shanagar
  • Patent number: 8883735
    Abstract: The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: November 11, 2014
    Assignee: Novartis AG
    Inventors: David Jenkins, Ming Lei, Andreas Loew, Li Zhou
  • Publication number: 20140328794
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.
    Type: Application
    Filed: July 18, 2013
    Publication date: November 6, 2014
    Applicant: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
  • Patent number: 8877711
    Abstract: A method is described that improves the transport properties of albumin produced on an industrial scale, wherein the albumin is mixed, during the production process, with substances that saturate the binding points on the albumin. Furthermore, pasteurized and then octanoate-reduced human albumin and therapeutic uses of such albumin is described. Such albumin may be useful in detoxifying human plasma, e.g. for the intravenous treatment of acute or chronic liver diseases, and as a dialysate in extracorporeal liver dialysis.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: November 4, 2014
    Assignee: CSL Behring GmbH
    Inventors: Peter Kiessling, Dietrich Bosse, Johannes Zeiss, Gaston Diderrich
  • Patent number: 8865647
    Abstract: If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: October 21, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Helle Naver, Svend Havelund, Peter Madsen
  • Patent number: 8858917
    Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: October 14, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Edwards, Howard A. Stone
  • Publication number: 20140303084
    Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.
    Type: Application
    Filed: June 9, 2012
    Publication date: October 9, 2014
    Applicant: Biogen IDEC MA Inc.
    Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
  • Patent number: 8846771
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: September 30, 2014
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Publication number: 20140256636
    Abstract: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Seetharama A. Acharya, Belur N. Manjula
  • Publication number: 20140235825
    Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.
    Type: Application
    Filed: February 11, 2014
    Publication date: August 21, 2014
    Applicant: Tenaxis Medical, Inc.
    Inventors: Ronald Dieck, Ian J. Handley, Neil Winterbottom, Joanna Wong
  • Publication number: 20140228292
    Abstract: The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.
    Type: Application
    Filed: July 9, 2012
    Publication date: August 14, 2014
    Applicant: ARTS BIOLOGICS A/S
    Inventors: Peter Nordkild, Svend Lindenberg, Claus Yding Andersen, Kim Vilbour Andersen
  • Publication number: 20140227717
    Abstract: Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 14, 2014
    Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
  • Publication number: 20140213511
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Application
    Filed: January 27, 2014
    Publication date: July 31, 2014
    Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
  • Publication number: 20140213765
    Abstract: A tissue scaffold that made of albumin having continuous solid network and void are disclosed. Methods for preparing albumin tissue scaffolds from animal albumins are also disclosed.
    Type: Application
    Filed: January 25, 2013
    Publication date: July 31, 2014
    Inventor: I-Liang Lee
  • Patent number: 8765915
    Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
    Type: Grant
    Filed: February 3, 2007
    Date of Patent: July 1, 2014
    Assignee: CSL Behring GmbH
    Inventors: Thomas Weimer, Stefan Schulte, Ulrich Kronthaler, Wiegand Lang, Uwe Liebing, Wilfried Wormsbächer
  • Patent number: 8754194
    Abstract: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: June 17, 2014
    Assignee: CSL Behring GmbH
    Inventors: Stefan Schulte, Thomas Weimer, Hubert Metzner
  • Publication number: 20140162936
    Abstract: The present invention relates to a polypeptide binding to a chymase (EC 3, 4, 21,39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X1)A(X2)(X3)(X4)(X5) (X6)LSFHKGEKFQIL(X7 (X8)(X9)(X10) (X11)(X12)G(X13)(X14)WEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X1) is R, N, Q, E, K, H, S, T, C, or D; (X2) is E, T, D, Q, L, P, A, S, C, M, N, E, G, A, V or I; (X3) is R, T, H, N, K, S, C, N or Q; (X4) is S, W, T, C, N, Q, For Y; (X5) is T, H, L, F, C, S, M, N, Q, R, K, G, A, V, I, P, Y or W; (X6) is D, Q, H, E, S, T, C, N, R or K; (X7) is D, N, R, E, Q, S, T, C, K or D; (X8) is M, W, G, F, A, S, T, C, S, N, Q, Y, V, L, I or P; (X9) is T, H, S, D, C, N, Q, R, K, E or absent; (X10) is V, T, Q, G, A, L, I, P, S, C, M, N or absent; (X11) is P, A, D, G, K, V, L, I, E, R, M, H or absent; (X12) is N, V, P, I, E, T, S, A, G, L, C, M, Q or D; (X13) is D, E, T, P, G, A, V, L, I, S, C, M, N or Q, and (X14) is W, Y, L, G, A, V, I, P, M, or F; (b)
    Type: Application
    Filed: April 24, 2012
    Publication date: June 12, 2014
    Applicant: COVAGEN AG
    Inventors: Simon Brack, Sarah Batey, Dragan Grabulovski, Julian Bertschinger, Daniel Schlatter, Jörg Benz, David Banner, Michael Hennig
  • Patent number: 8748380
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: June 10, 2014
    Assignee: Novozymes Biopharma DK A/S
    Inventors: Andrew Plumridge, Darrell Sleep, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20140155325
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: November 20, 2013
    Publication date: June 5, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Publication number: 20140154272
    Abstract: The invention provides a compound of formula (I), wherein R1 is H, C(NH)NH2, an amino acid, or a peptide; X is OH, NH2, NHR2, NR2R3, an amino acid, or a peptide; R2 and R3 are selected from alkyl, alkylenearyl, or alkyleneheteroaryl; each R4 and R5 is independently H or CH3; Z is 2-amino-2,3-dihydro-1H-indene-2-carboxylic acid; 2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid; 6-amino-6,7,8,9-tetrahydro-5H-benzo[7]annulene 6-carboxylic acid; cyclohexylalanine; cyclohexylglycine; homophenylalanine; 1-naphthylalanine; 2-naphthylalanine; 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; or octahydro-1H-indole-2-carboxylic acid; n is 0, 1, 2, 3, or 4; with the proviso that X is not NH2 when R1 is H, R4 is H, R5 is CH3, Z is Aci, and n is 2; or a pharmaceutically acceptable salt, ester or solvate thereof. A method of treating pain and a method for treating a mu-opioid receptor mediated disorder and/or a delta-opioid receptor mediated disorder also are provided.
    Type: Application
    Filed: June 22, 2012
    Publication date: June 5, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Henry I. Mosberg
  • Publication number: 20140155326
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: November 21, 2013
    Publication date: June 5, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Patent number: 8741832
    Abstract: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: June 3, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Seetharama A. Acharya, Belur N. Manjula
  • Patent number: 8741662
    Abstract: Methods and kits for diagnosis and prognosis using biomarkers comprising albumin-bound protein/peptide complex (ABPPC).
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: June 3, 2014
    Assignee: The Johns Hopkin University
    Inventors: Jennifer E. Van Eyk, Rebekah Lynn Gundry, Robert J. Cotter
  • Publication number: 20140141488
    Abstract: Sequence of 55 New Found Proteins—2 new proteins in Cryoprecipitate—8 new proteins in Fraction III—8 new proteins in Prothrombin Complex Concentrate—2 new found proteins in AFCC (Fraction 33)—3 new proteins in Fraction IV and 4 new found proteins in AFOD (Fraction 42)—2 in HemoRAAS®, 3 in FibroRAAS®, 5 in GammaRAAS®, 3 in AFCC®, 1 in Fraction 3-2, 2 in Fraction 3, 4 in FibingluRAAS® (Thrombin), 3 in AFOD®, 1 in AlbuRAAS®, 1 in FibingluRAAS® (High concentrate Fibrinogen), 1 in AFCC® (From fraction IV), 2 in Transferrin from Human Plasma and their name KH1 through KH55, and 16 existing proteins in which good KH healthy cells exists and their application.
    Type: Application
    Filed: January 31, 2013
    Publication date: May 22, 2014
    Inventor: Kieu Hoang
  • Patent number: 8715718
    Abstract: Compositions, methods, and kits for repair and production of extracellular matrix are provided. In the broad aspect, the composition comprises a ligand of ?5?1 integrin attached to a surface of a nanoparticle composed of a protein, with a proviso that the protein is not fibronectin.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: May 6, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Prabhas V. Moghe, Ram Sharma, Marian Pereira Guelakis
  • Publication number: 20140093981
    Abstract: The method of the present disclosure is characterized by that one molecule of the amino acid is interposed between the self-assembled monolayer and the molecule of the albumin. For example, a method is provided for immobilizing albumin on a self-assembled monolayer, the method including the following steps (a) and (b) in this order: a step (a) of preparing a substrate including one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the albumin to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecule of the amino acid and the amino group of the albumin.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: PANASONIC CORPORATION
    Inventor: Yukari HATAOKA
  • Patent number: 8686225
    Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: April 1, 2014
    Assignee: Ventria Bioscience Inc.
    Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
  • Patent number: 8685923
    Abstract: A method for inhibiting survival of cancer cells in a subject is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of fibrillar albumin. The preparation of the fibrillar albumin comprises: (i) forming a solution comprising an isolated and/or purified globular albumin; (ii) adding a detergent to the solution containing the isolated and/or purified globular albumin, wherein the detergent is one selected from the group consisting of sodium dodecyl sulfate (SDS) and n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate; (iii) applying the solution to a molecular sizing column with a pore size that permits separation of a protein with a molecular weight of at least about 70 kDa so as to promote column-induced formation of the fibrillar albumin from the isolated and/or purified globular albumin; and (iv) eluting the fibrillar albumin from the column, wherein the eluted albumin has a fibrillar structure.
    Type: Grant
    Filed: August 12, 2012
    Date of Patent: April 1, 2014
    Assignee: Academia Sinica
    Inventors: Shu-Mei Liang, Chun-Yung Huang, Chi-Ming Liang
  • Publication number: 20140086949
    Abstract: Immunoconjugates for impeding weight gain and treating obesity in a subject are disclosed. The immunoconjugates comprise a ghrelin mimetic polypeptide hapten, a spacer moiety comprising one of more polyethylene glycol (PEG) units, and a protein carrier moiety. Immunoconjugates optionally include a conjugation moiety for conjugating the polypeptide hapten with a linker moiety or the protein carrier moiety and a linker moiety for conjugating the conjugation moiety with the protein carrier moiety.
    Type: Application
    Filed: February 9, 2012
    Publication date: March 27, 2014
    Inventors: Kim D. Janda, Alexander V. Mayorov
  • Patent number: 8680315
    Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: March 25, 2014
    Assignee: Prolynx, LLC
    Inventors: Daniel V. Santi, Gary W. Ashley
  • Publication number: 20140072561
    Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.
    Type: Application
    Filed: September 17, 2013
    Publication date: March 13, 2014
    Applicant: CSL BEHRING GMBH
    Inventors: Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
  • Publication number: 20140066378
    Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.
    Type: Application
    Filed: July 13, 2013
    Publication date: March 6, 2014
    Inventors: Surjit Bhimarao DIXIT, Igor Edmondo Paolo D'ANGELO, Mario SANCHES, Gordon Yiu Kon NG
  • Publication number: 20140066370
    Abstract: The disclosure provides Polypeptide Conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity.
    Type: Application
    Filed: November 23, 2010
    Publication date: March 6, 2014
    Applicant: Amylin Pharmaceuticals, LLC
    Inventors: Behrouz Bruce Forood, Soumitra S. Ghosh, James L. Trevaskis, Chengzao Sun, Odile Esther Levy, Lawrence J. D'Souza, Christopher J. Soares
  • Publication number: 20140056921
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Application
    Filed: June 6, 2013
    Publication date: February 27, 2014
    Applicant: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly H. Tabor
  • Publication number: 20140046027
    Abstract: The present invention concerns a method of modifying the surface of a cellulosic material, wherein a modifying compound is attached to the cellulosic material through a linker, which linker is a conjugate that has been activated by functionalization prior to adsorption to form an activated conjugate, and wherein the entire method is carried out in aqueous media, as well as an intermediate product suitable for attaching to a modifying compound, the intermediate product comprising said functionalized conjugate linker that has been adsorbed to a cellulosic material.
    Type: Application
    Filed: March 7, 2012
    Publication date: February 13, 2014
    Applicant: AALTO UNIVERSITY FOUNDATION
    Inventors: Janne Laine, Sami Nummelin, Eero Kontturi, Olli Ikkala, Ilari Filpponen, Henna Rosilo
  • Publication number: 20140041547
    Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.
    Type: Application
    Filed: October 16, 2013
    Publication date: February 13, 2014
    Applicant: Tenaxis Medical, Inc.
    Inventors: Ronald Dieck, Ian J. Handley, Neil Winterbottom, Joanna Wang